# US 2025/0152694 A1 · Methods and compositions for multivalent vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152694 A1
- Document ID: US20250152694A1
- Status: Published application
- Kind: A1
- Application number: 18/942,731
- Filed: 2024-11-10
- Published: 2025-05-15
- Earliest claimed: 2023-11-10
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, The University of Texas System
- Inventors: Zackary Armstrong; Karl Klose; Xhavit Zogaj
- Web page: https://patentgrep.com/patent/US20250152694A1

## CPC

- A61K 39/116: Polyvalent bacterial antigens
- A61K 39/0291: {Yersinia}
- A61K 39/07: Bacillus
- C07K 14/24: from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K 14/32: from Bacillus (G)
- C12N 1/20: Bacteria; Culture media therefor
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/70: {Multivalent vaccine}
- C07K 2319/034: containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
- C07K 2319/035: containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Certain embodiments are directed to an attenuated bacterial platform for autotransporter-mediated display of antigens. In certain aspects the display is surface display or periplasmic display. In other aspects the antigen is a microbial antigen. The microbial antigen can be a bacterial or viral antigen. The antigen can be antigen derived from a biothreat.

## Claims

### Claim 1

A live attenuated Francisella novicida bacterium expressing a heterologous antigen of a second biothreat, the heterologous antigen being operably coupled to a leader sequence or surface protein that localizes the heterologous antigen in the periplasm or on the surface of the live attenuated Francisella novicida bacteria.

### Claim 2 (depends on 1)

The live attenuated Francisella novicida bacterium of claim 1, wherein the surface protein is an autotransporter translocator domain.

### Claim 3 (depends on 2)

The live attenuated Francisella novicida bacterium of claim 2, wherein the autotransporter is YfaL.

### Claim 4 (depends on 1)

The live attenuated Francisella novicida bacterium of claim 1, wherein the leader sequence is selected from PelB, PepO, or TorA.

### Claim 5 (depends on 1)

The live attenuated Francisella novicida bacterium of claim 1, wherein two heterologous antigens are expressed as a fusion protein.

### Claim 6 (depends on 5)

The live attenuated Francisella novicida bacterium of claim 5, wherein two heterologous antigens expressed as a fusion are separated by a self-cleaving amino acid sequence once translated.

### Claim 7 (depends on 5)

The live attenuated Francisella novicida bacterium of claim 5, wherein two heterologous antigens are independently translated from a polycistronic mRNA.

### Claim 8 (depends on 1)

The live attenuated Francisella novicida bacterium of claim 1, wherein the second biothreat antigen is a Category A, Category B, and/or Category C antigen.

### Claim 9 (depends on 8)

The live attenuated Francisella novicida bacterium of claim 8, wherein the Category A agent is Bacillus anthracis (Anthrax), Clostridium botulinum toxin (Botulism), Yersinia pestis (Plague), pox viruses, Francisella tularensis (Tularemia), Viral hemorrhagic fevers (Filoviruses like Ebola and Marburg, and Arenaviruses like Lassa), or smallpox.

### Claim 10 (depends on 1)

The live attenuated Francisella novicida bacterium of claim 1, wherein the second biothreat antigen is from Yersinia pestis (Yp) or Bacillus anthracis (Ba).

### Claim 11 (depends on 1)

The live attenuated Francisella novicida bacterium of claim 1, expressing a Yersinia pestis (Yp) antigen and a Bacillus anthracis (Ba) antigen.

### Claim 12 (depends on 11)

The live attenuated Francisella novicida bacterium of claim 11, wherein the Yp antigen is LcrV and the Ba antigen is a BA protective antigen (PA).

### Claim 13

Attenuated Francisella bacterium expressing one or more heterologous antigen, the one or more heterologous antigen being operably coupled to an autotransporter translocator domain.

### Claim 14 (depends on 13)

The attenuated bacterium of claim 13, wherein the autotransporter is YfaL.

### Claim 15 (depends on 13)

The attenuated bacterium of claim 13, wherein the one or more heterologous antigen is a Category A, Category B, and/or Category C antigen.

### Claim 16 (depends on 15)

The attenuated bacterium of claim 15, wherein the Category A agent is Bacillus anthracis, Clostridium botulinum toxin, Yersinia pestis, Francisella tularensis, Viral hemorrhagic fever, or smallpox.

### Claim 17 (depends on 13)

The attenuated bacterium of claim 13, wherein the one or more heterologous antigen is a Yersinia pestis (Yp) antigen or Bacillus anthracis (Ba) antigen.

### Claim 18 (depends on 17)

The attenuated bacterium of claim 17, wherein the Yp antigen is LcrV and the Ba antigen is a BA protective antigen (PA).

### Claim 19 (depends on 13)

The attenuated bacterium of claim 13, wherein the attenuated bacterium is an attenuated Francisella novicida bacterium.

### Claim 20 (depends on 19)

The attenuated bacterium of claim 19, wherein the Francisella novicida bacterium is a KKF768 bacterium.
